Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 547-552 , November 2009

Future directions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates

  • Mohammed Mohiuddin

      Affiliations

    • Geisinger Cancer Institute, 1000 E. Mountain Blvd., Wilkes Barre, PA 18711, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 570 332 1108; fax: +1 570 819 5485.
    • ,
  • Majid M. Mohiuddin

      Affiliations

    • Department of Radiation Oncology, University of Maryland, 22 S Green Street, Baltimore, MD 21201, United States
    • ,
  • John Marks

      Affiliations

    • Main Line Health System, Lankenau Institute for Medical Research, MOB West, Suite 330, 100 East Lancaster Avenue, Wynnewood, PA 19096, United States
    • ,
  • Gerald Marks

      Affiliations

    • Main Line Health System, Lankenau Institute for Medical Research, MOB West, Suite 330, 100 East Lancaster Avenue, Wynnewood, PA 19096, United States

Received 24 March 2009 ,Revised 6 May 2009 ,Accepted 11 May 2009.

References 

  1. Carlomagno C, Farella A, Buccci L, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 10.1093/annonc.2009.719.
  2. Rosenthal DI, Catalano DJ, Haller D, et al. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys. 2008;72:108–113
  3. Shivnani AT, Small W, Stryker SJ, et al. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007;193:389–393
  4. Rodel C, Liersch T, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110–117
  5. Aschele C, Friso ML, Pucciarelli S, et al. A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 10.1093/annonc.2005.212.
  6. Glynne-Jones R, Sebag-Montefiore D, Samuel L, et al. Socrates phase II study results: capecitabine (CAP) combined with oxaliplat (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer. J Clin Oncol 2005;16(June 1 Suppl.):S 3527.
  7. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–8696
  8. Crane CH, Skibber JM, Feig BW, et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003;97:517–524
  9. Roh MS, Colangelo L, Wieand S, et al. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. J Clin Oncol 2004;22(July 15 Suppl.):14S [abstr 3505].
  10. Czito BG, Bendell JC, Willett C, et al. Bevacizumab, oxaliplatin, capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys. 2007;68:472478
  11. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 10.1016/ijrobp2008.10.014.
  12. Jakobsen A, Mortensen JP, Bisgaard C, et al. A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. Int J Colorectal Dis. 2007;23:251–255
  13. Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys. 2008;72:644–649
  14. Peeters KC, Marijnen CA, Nagtegaal ER, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693–701
  15. Visser O, Bakx R, Zoetmulder FAN, et al. The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in Greater Amsterdam. J Surg Oncol. 2007;95:447–454
  16. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731–1740
  17. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European organisation for research and treatment of cancer radiation oncology group. J Clin Oncol. 2007;25:4379–4386
  18. Lefebvre JL, Rolland F, Tesselaar E, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy. J Natl Cancer Inst 10.1093/JNCI.2009.460.
  19. Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008;35:221–228
  20. Nagai K, Tsuchiya R, Mori T, et al. Lung cancer surgical study group of the Japan clinical oncology group. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;125:254–260
  21. Vokes EE, Herndon JE, Kelley MJ, et al. Cancer and leukemia group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and leukemia group B. J Clin Oncol. 2007;25:1698–1704
  22. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–1921
  23. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–674
  24. Glynne-Jones R, Grainger J, Harrison M, et al. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. Brit J Cancer. 2006;94:363–371
  25. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) (Initial report of Radiation Therapy Oncology Group (RTOG). In: 9th world conference on lung cancer (IASCLC). Tokyo, Japan; 2000 [abstr 9410].
  26. Glynne-Jones R, Hoskins P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?. J Clin Oncol. 2007;25:5281–5286
  27. NSABP R-04: Phase III randomized study of preoperative chemoradiotherapy comprising radiation therapy and either capecitabine or fluorouracil with or without oxaliplatin in patients with resectable rectal cancer. NSABP protocol. Protocol ID, NCT00058474, CALGB-NSABP-R-04.
  28. Higgins CA, Humphrey EW, Dwight RW, et al. Preoperative radiation, surgery for cancer of the rectum: Veterans Administration Surgical Oncology Group trial 11. Cancer. 1986;58:352
  29. Medical Research Council Working Party . Randomized trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet. 1996;348:1605–1610
  30. James RD. The Northwest of England rectal cancer trial. Recent results in Cancer Res. 1988;110:104–110
  31. Gerard A, Buyse M, Nordinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal carcinoma. Ann Surg. 1988;208:606–614
  32. Withers HR, Taylor JM, Maciejewski B, et al. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  33. Willet C, Warland G, Hagan M. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol. 1995;113:1417–1424
  34. Fleckenstein K, Zgonjanin L, Chen L, et al. Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. Int J Radiat Oncol Biol Phys. 2007;68:196–204
  35. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–1733
  36. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  37. Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in resectable rectal cancer. New Engl J Med. 1997;336:980–987
  38. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15–24
  39. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Brit J Surg. 2006;93:1215–1223
  40. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?. Int J Radiat Oncol Biol Phys. 2008;71:1181–1188
  41. Habr-Gama A, Perez RO. Can we increase the rates of complete response by adding chemotherapy to neoadjuvant CRT regimen for distal rectal cancer? Results of a prospective study using additional chemotherapy during the resting period of neoadjuvant CRT: personal communication. Abstract submitted for presentation at annual meeting of American society of colon and rectal surgeons, May 2–6, 2009.
  42. Fietkau R, Rodel C. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys. 2007;68:1580–1581
  43. Suwinski R, Taylor JM, Withers HR. Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1998;42:943–951
  44. Overgaard M, Overgaard J, Sell A. Dose–response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. Radiother Oncol. 1984;1:217–225
  45. Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–1139
  46. Mohiuddin M, Lingareddy V, Rakinic J, et al. Re-irradiation for rectal cancer and surgical resection after ultra high doses. Int J Radiat Oncol Biol Phys. 1993;27:1159–1163
  47. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650–655
  48. Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2006;64:709–716
  49. Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys. 2000;46:883–888
  50. Chan AK, Wong AO, Langevin J, et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys. 2000;48:843–856
  51. Choi JH, et al. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose. Jpn J Clin Oncol. 2008;38:12–21
  52. Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplat with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol. 2008;26:[Suppl; abstr 4021]
  53. Lingareddy V, Mohiuddin M, Marks G. The importance of patient selection for adjunctive postoperative radiation therapy for cancer of the rectum. Cancer. 1994;73(7):805–1810
  54. Allee PE, Tepper JE, Gunderson LL, et al. Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int J Radiat Oncol Biol Phys. 1989;17:1171–1176
  55. Wu X, Gu J, Swisher SG, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789–3798
  56. Amando RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  57. Cervantes A, Macarulla T, Martinelli E, et al. Correlation of KRAS status (wild type (wt) vs. mutant >) with efficacy to first-line cetuximab+FOLFIRI in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2008;26:4129
  58. Cohn A, Smith D, Neubauer M, et al. Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT); effect of KRAS mutation status on second-line treatment with pmab and FOLFIRI. J Clin Oncol. 2008;26:4127
  59. Bokemeyer C, Bondarenko I, Hartmann J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol. 2008;26:400
  60. Van Cutsem E, Lang I, D’Haens G, et al. KRAS status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol 2008;19(Suppl. 8):710.
  61. Gillies W, McKenna R, Muschel J, et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene. 2008;22:5866–5875
  62. Toulany M, Kittmann K, Kruger M, et al. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI13K-AKT pathway. Radiother Oncol. 2005;36:143–150
  63. Li S, Kim JS, Kim JM, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006;65:705–712
  64. Bengala C, Bettelli S, Bertolini F, et al. Predictive value of EGFR gene copy number and K-ras mutation for pathological response to preoperative cetuximab, 5FU, and radiation therapy in locally advanced rectal cancer (LARC). J Clin Oncol 2008;26(No. 15S, May 20 Suppl.):4125.
  65. Wang YB, Cummings B, Cotton P, et al. Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol. 2005;77:126–132
  66. Derdel J, Mohiuddin M, Kramer S, Marks G. Is dose/time fractionation important in treating rectal cancer?. Int J Radiat Oncol Biol Phys. 1985;11:579–582
  67. Haveman J, Castro-Kreder N, Rodermond HM, et al. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep. 2004;12:187–192
  68. Mohiuddin M, Chendil D, Dey S, et al. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cell lines. Anticancer Res. 2002;22:825–830
  69. Stockholm Colorectal Cancer Study Group . Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol. 1996;3:423–430
  70. Papillon J, Gerard JP. Role of radiotherapy in anal preservation for cancers of the lower third of the rectum. Int J Radiat Oncol Biol Phys. 1990;19:1219–1220
  71. Gerard JP. The use of radiotherapy for patients with low rectal cancer: an overview of the Lyon experience. Aust NZ J Surg. 1994;64:457–463
  72. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer is the same in Japan and the West. Brit J Surg. 2008;95:33–48
  73. Yu TK, Bhosale PR, Crane C, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:1175–1180
  74. Kusters M, Van de Velde CJ, Beets-Tan RG, et al. Patterns of local recurrence in rectal cancer: a single-center experience. Ann Surg Oncol. 2009;16:289–296
  75. Syk E, Torkzad M, Blomqvist M, et al. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008;3:1658–1664

PII: S0305-7372(09)00082-6

doi: 10.1016/j.ctrv.2009.05.002

Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 547-552 , November 2009

Article Tools

* Image Usage & Resolution